Early and late responses in patients with rheumatoid arthritis who were conventional synthetic disease-modifying anti-rheumatic drug inadequate responders and were treated with tocilizumab or switched to rituximab: an open-label phase 3 trial (MIRAI)

To evaluate early and late responses in biological-naïve patients with rheumatoid arthritis (RA) initiating tocilizumab and early tocilizumab non-responders who switched to rituximab. In this open-label, non-randomised phase 3 study, RA patients with inadequate response to conventional synthetic DMA...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical and experimental rheumatology 2019-11, Vol.37 (6), p.937-945
Hauptverfasser:	Dörner, Thomas, Schulze-Koops, Hendrik, Burmester, Gerd-Rüdiger, Iking-Konert, Christof, Schmalzing, Marc, Engel, Andreas, Kästner, Peter, Kellner, Herbert, Kurthen, Reiner, Krüger, Klaus, Rubbert-Roth, Andrea, Schwenke, Holger, Peters, Marvin A, Tony, Hans-Peter
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal, Humanized - therapeutic use Antirheumatic Agents - therapeutic use Arthritis, Rheumatoid - drug therapy Double-Blind Method Humans Remission Induction Rituximab - therapeutic use Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!